Hartford Investment Management Co. Trims Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Hartford Investment Management Co. cut its position in Hologic, Inc. (NASDAQ:HOLX) by 1.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,792 shares of the medical equipment provider’s stock after selling 173 shares during the period. Hartford Investment Management Co.’s holdings in Hologic were worth $1,205,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Lecap Asset Management Ltd. acquired a new position in Hologic in the 3rd quarter worth approximately $493,000. Signaturefd LLC boosted its holdings in shares of Hologic by 13.3% in the 3rd quarter. Signaturefd LLC now owns 2,186 shares of the medical equipment provider’s stock valued at $178,000 after acquiring an additional 257 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Hologic by 2.4% during the third quarter. Sequoia Financial Advisors LLC now owns 7,388 shares of the medical equipment provider’s stock worth $602,000 after purchasing an additional 173 shares during the last quarter. Everence Capital Management Inc. acquired a new position in Hologic during the third quarter valued at $389,000. Finally, Prentiss Smith & Co. Inc. boosted its holdings in Hologic by 0.3% in the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after purchasing an additional 130 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares in the company, valued at approximately $310,415.85. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now owns 10,476 shares in the company, valued at approximately $858,927.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on HOLX. Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Evercore ISI boosted their price target on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Mizuho upped their price objective on Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Leerink Partners cut their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average price target of $87.50.

Hologic Price Performance

NASDAQ:HOLX opened at $80.83 on Friday. The firm has a market cap of $18.86 billion, a P/E ratio of 41.24, a price-to-earnings-growth ratio of 2.89 and a beta of 0.98. The stock has a 50 day moving average of $80.92 and a two-hundred day moving average of $77.86. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company earned $0.93 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. On average, analysts expect that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.